MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
893 produits trouvés pour "MAPK". Les 500 premiers sont affichés.
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
RTIL 13
CAS :RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).Formule :C30H55BrN2O3Couleur et forme :SolidMasse moléculaire :571.685Mitogen-activated protein kinase 1
CAS :Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.Degré de pureté :98%Couleur et forme :SolidS6 Kinase Substrate Peptide 32
S6 Kinase Substrate Peptide 32 is a peptide that measures the activity of kinases that phosphorylate ribosomal protein S6. It can also be used as a substrate.Formule :C149H270N56O49Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :3630.1MS432
MS432 is a highly selective PD0325901-based VHL-recruiting PROTAC degrader for MEK1 and MEK2.Formule :C50H65F3IN7O6SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1076.06GGDPS-IN-1
GGDPS-IN-1 (Compound 37) is an inhibitor of geranylgeranyl diphosphate synthase (GGDPS) with an IC50 of 49.4 nM, disrupting protein geranylgeranylation in myeloma cells.Formule :C15H28N4O6P2Couleur et forme :SolidMasse moléculaire :422.14841KRAS G12C inhibitor 60
KRAS G12C Inhibitor 60 (compound 23), a selective inhibitor targeting the Kras-G12C mutation, is utilized in the investigation of lung, colorectal, andFormule :C31H30F5N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :627.61Rac1 Inhibitor W56
CAS :Peptide (45-60) blocks Rac1 binding with TrioN, GEF-H1, Tiam1 GEFs.Formule :C74H117N19O23SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1671.93R18
CAS :14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.Formule :C101H157N27O29S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2309.69Tagarafdeg
CAS :Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.Formule :C45H49F2N11O9SDegré de pureté :99.34% - ＞99.99%Couleur et forme :SolidMasse moléculaire :958HPK1-IN-4
CAS :HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.Formule :C23H26N6O3Degré de pureté :97.06%Couleur et forme :Yellow SolidMasse moléculaire :434.49Ref: TM-T40350
1mg123,00€5mg295,00€1mL*10mM (DMSO)326,00€10mg447,00€25mg782,00€50mg1.071,00€100mg1.468,00€(S,R,S)-AHPC-Me-C10-Br
CAS :(S,R,S)-AHPC-Me-C10-Br is a chemically synthesized conjugate and ligand-linker for E3 ligase, MS432 for MEK1/2 inhibitors and a VHL E3 ligase linker.Formule :C34H51BrN4O4SDegré de pureté :98.89%Couleur et forme :SolidMasse moléculaire :691.76ASP6918
ASP6918 is a potent, orally active KRAS G12C inhibitor with an IC50 of 0.028 µM. It inhibits cell growth and demonstrates antitumor activity.Formule :C36H43N7O3Couleur et forme :SolidMasse moléculaire :621.34274Antimicrobial agent-21
CAS :Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment ofFormule :C18H13N3OSDegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :319.38Ref: TM-T67942
1mg54,00€5mg116,00€10mg172,00€1mL*10mM (DMSO)180,00€25mg278,00€50mg371,00€100mg510,00€200mg687,00€Fluconazole-PEG6-XMU-MP-9
Fluconazole-PEG6-XMU-MP-9, PEG-linked conjugate, fluconazole antifungal plus XMU-MP-9, promotes Nedd4-1 mediated K-Ras mutant degradation.Formule :C48H53F3N10O10SDegré de pureté :98.73%Masse moléculaire :1019.06ERK1/2 inhibitor 10
ERK1/2 inhibitor 10 (Compound 36c) is a potent inhibitor of ERK1 and ERK2, with IC50 values of 0.11 nM and 0.08 nM, respectively. It effectively hinders the phosphorylation of downstream substrates p90RSK and c-Myc. Additionally, ERK1/2 inhibitor 10 induces apoptosis and incomplete autophagy-related cell death. This compound demonstrates significant antitumor efficacy in models of triple-negative breast cancer and colorectal cancer harboring BRAF and RAS mutations.Formule :C23H20ClN5O2SMasse moléculaire :465.10262DS03090629
DS03090629, an orally active MEK inhibitor, functions by competitively inhibiting MEK activity in the presence of ATP. This compound demonstrates strong binding affinity to both MEK and phosphorylated MEK, with dissociation constants (Kd) of 0.11 and 0.15 nM, respectively. It has shown efficacy in suppressing the proliferation of melanoma cell lines that overexpress BRAF mutations, achieving IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 is thus considered promising for anti-melanoma therapies.Formule :C25H26ClN5O2Couleur et forme :SolidMasse moléculaire :463.96PROTAC MEK1 Degrader-1
CAS :PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2Formule :C53H66FIN8O11S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1201.17HSND80
HSND80 (Compound 1) is an orally active MNK/p70S6K inhibitor, exhibiting a Kd value of 44 nM for MNK1 and 4 nM for MNK2. The residence time of HSND80 on MNK1 and MNK2 is 45 minutes and 58 minutes, respectively. HSND80 effectively inhibits non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppresses the growth of triple-negative breast cancer (TNBC) cells in vitro.Couleur et forme :Odour SolidKRAS-IN-43
KRAS-IN-43 (Compound 9) is a broad-spectrum KRAS inhibitor with IC50 values of 0.15 μM for KRASG12V, 0.14 μM for KRASG12C, and 0.47 μM for wild-type KRAS. It disrupts the interaction between KRAS and cRAF and suppresses ERK phosphorylation. KRAS-IN-43 shows potential for research in KRAS mutation-associated cancers, including pancreatic, colorectal, and lung cancers.Couleur et forme :Odour SolidNK7-902 TFA
NK7-902 TFA is a CRBN molecular glue degrader of NEK7. It effectively degrades NEK7 in human primary monocytes and whole blood, yet only partially inhibits NLRP3-dependent IL-1β production. While NK7-902 TFA achieves deep and lasting NEK7 degradation, it temporarily blocks NLRP3 inflammasome activation in non-human primates when administered orally. Additionally, NK7-902 TFA demonstrates activity in mouse systems.Couleur et forme :Odour Solid
